The EU executive is optimistic about negotiations regarding the pharmaceutical framework, despite requests from the pharmaceutical sector for changes. Companies like Sanofi and Novartis are lobbying for stronger intellectual property protections and reduced price controls. The Commission does not plan to withdraw the current proposal, emphasizing ongoing collaboration with lawmakers. Concerns about a potential trade war with the US are influencing industry pressures, leading to significant investments in US manufacturing by major firms. The Commission remains hopeful for a positive resolution and is committed to supporting the pharmaceutical industry. Teljes cikk (Euronews.com)